Inactivated Orf Virus Shows Antifibrotic Activity and Inhibits Human Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Replication in Preclinical Models

• Daniela Paulsen ,

  * E-mail: daniela.paulsen@aicuris.com

  Affiliation AiCuris GmbH & Co.KG, Wuppertal, Germany

  ⨯
• Andreas Urban,

  Affiliation AiCuris GmbH & Co.KG, Wuppertal, Germany

  ⨯
• Andreas Knorr,

  Affiliation Bayer HealthCare AG, Leverkusen, Germany

  ⨯
• Claudia Hirth-Dietrich,

  Affiliation Bayer HealthCare AG, Leverkusen, Germany

  ⨯
• Angela Siegling,

  Current address: Intellectual Property Management, Austria Wirtschaftsservice, Vienna, Austria

  Affiliation Bayer HealthCare AG, Leverkusen, Germany

  ⨯
• Hans-Dieter Volk,

  Affiliations Institute of Medical Immunology and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité – Medical University Berlin, Berlin, Germany, University of Heidelberg, Heidelberg, Germany

  ⨯
• Andrew A. Mercer,

  Affiliation Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand

  ⨯
• Andreas Limmer,

  Affiliation Institutes of Molecular Medicine and Experimental Immunology, University Hospital Bonn, Bonn, Germany

  ⨯
• Beatrix Schumak,

  Affiliation Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University of Bonn, Bonn, Germany

  ⨯
• Percy Knolle,

  Affiliations Institutes of Molecular Medicine and Experimental Immunology, University Hospital Bonn, Bonn, Germany, Institute of Molecular Immunology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany

  ⨯
• Helga Ruebsamen-Schaeff,

  Affiliation AiCuris GmbH & Co.KG, Wuppertal, Germany

  ⨯
• Olaf Weber

  Affiliation Bayer HealthCare AG, Leverkusen, Germany

  ⨯